Development of a plate-based optical biosensor fragment screening methodology to identify phosphodiesterase 10A inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3228-3234

  Geschwindner, Stefan ^a   Dekker, Niek ^a   Horsefield, Rob ^a   Tigerström, Anna ^a   Johansson, Patrik ^a   Scott, Clay W ^b   Albert, Jeffrey S ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE XAI INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; DRUG BINDING SITE; DRUG SCREENING; DRUG STRUCTURE; IC 50; OPTICAL BIOSENSOR; SURFACE PLASMON RESONANCE;

BIOSENSING TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SURFACE PLASMON RESONANCE;

EID: 84876862241     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301665y     Document Type: Article

References (21)

1. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned Nature Rev. Drug Discovery 2007, 6, 211-219
2. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680
3. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 2001, 41, 856-864
4. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
5. Hubbard, R. E.; Murray, J. B. Experiences in fragment-based lead discovery Methods Enzymol. 2011, 493, 509-531
6. Leach, A. R.; Hann, M. M. Molecular complexity and fragment-based drug discovery: ten years on Curr. Opin. Chem. Biol. 2011, 15, 489-496
7. Lepre, C. A. Practical aspects of NMR-based fragment screening Methods Enzymol. 2011, 493, 219-239
8. Holdgate, G. A.; Anderson, M.; Edfeldt, F.; Geschwindner, S. Affinity-based, biophysical methods to detect and analyze ligand binding to recombinant proteins: matching high information content with high throughput J. Struct. Biol. 2010, 172, 142-157
9. Dalvit, C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques Drug Discovery Today 2009, 14, 1051-1057
10. Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W. One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules J. Am. Chem. Soc. 1997, 119, 12257-12261
11. Jahnke, W.; Erlanson, D. A. Fragment-Based Aproaches to Lead Discovery; Wiley: Weinheim, Germany, 2007.
12. Danielson, U. H. Fragment Library Screening and Lead Characterization using SPR Biosensors Curr. Top. Med. Chem. 2009, 9, 1725-1735
13. Giannetti, A. M. From experimental design to validated hits: a comprehensive walk-through of fragment lead identification using surface plasmon resonance Methods Enzymol. 2011, 493, 169-218
14. Geschwindner, S. Industrial biophysics at the outlook for better leads: accelerating lead generation using affinity-based, label-free methods Int. Drug Discovery 2010, 5 (32) 34-36
15. Geschwindner, S.; Olsson, L.-L.; Albert, J. S.; Deinum, J.; Edwards, P. D.; de Beer, T.; Folmer, R. H. A. Discovery of a Novel Warhead against beta-Secretase through Fragment-Based Lead Generation J. Med. Chem. 2007, 50, 5903-5911
16. Geschwindner, S.; Carlsson, J. F.; Knecht, W. Application of Optical Biosensors in Small-Molecule Screening Activities Sensors 2012, 12, 4311-4323
17. Cunningham, B. T.; Li, P.; Schulz, S.; Lin, B.; Baird, C.; Gerstenmaier, J.; Genick, C.; Wang, F.; Fine, E.; Laing, L. Label-free assays on the BIND system J. Biomol. Screening 2004, 9, 481-490
18. Fang, Y.; Ferrie, A. M.; Fontaine, N. H.; Mauro, J.; Balakrishnan, J. Resonant waveguide grating biosensor for living cell sensing Biophys. J. 2006, 91, 1925-1940
19. Bauer, U.; Giordanetto, F.; Bauer, M.; O'Mahony, G.; Johansson Kjell, E.; Knecht, W.; Hartleib-Geschwindner, J.; Carlsson Eva, T.; Enroth, C. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 1944-1948
20. O'Mahony, G.; Bauer, U. Unpublished results.
21. Cantin, D.; Magnuson, S.; Gunn, D.; Bullock, W.; Burke, J.; Fu, W.; Kumarasinghe, E. S.; Liang, S. X.; Newcom, J.; Ogutu, H.; Olague, A.; Wang, M.; Wickens, P.; Zhang, Z.; Bierer, D. Preparation of phenyl-substituted quinoline and quinazoline amino acid derivatives for the treatment of diabetes. Patent WO2006034512, 2006.